| **Characteristic** | **BCC** N = 5*1* | **MCC** N = 5*1* | **SCC** N = 11*1* |
| --- | --- | --- | --- |
| Age [yrs] (sd) | 77 (13) | 69 (1) | 74 (10) |
| Sex (%) |  |  |  |
| Female | 3 (60%) | 1 (20%) | 4 (36%) |
| Male | 2 (40%) | 4 (80%) | 7 (64%) |
| Treatment (%) |  |  |  |
| Avelumab(anti-PD1/PDL1) | 0 (0%) | 1 (20%) | 0 (0%) |
| Cemiplimab(anti-PD1/PDL1) | 0 (0%) | 0 (0%) | 7 (64%) |
| Nivolumab(anti-PD1/PDL1) | 4 (80%) | 1 (20%) | 0 (0%) |
| Nivolumab(anti-PD1/PDL1)+Ipilimumab(anti-CTLA4) | 1 (20%) | 0 (0%) | 0 (0%) |
| Pembrolizumab(anti-PD1/PDL1) | 0 (0%) | 3 (60%) | 4 (36%) |
| ICI Response (%) |  |  |  |
| Nonresponder/NR | 1 (20%) | 1 (20%) | 4 (36%) |
| Other (radiotherapy, organ transplant, unevaluable) | 0 (0%) | 1 (20%) | 3 (27%) |
| Responder/R | 2 (40%) | 3 (60%) | 4 (36%) |
| Stable\_Disease/SD | 2 (40%) | 0 (0%) | 0 (0%) |
| Prior Treatment |  |  |  |
| Immunotherapy | 0 (0%) | 1 (20%) | 0 (0%) |
| Targted | 3 (60%) | 0 (0%) | 3 (27%) |
| Immunotherapy+Targted | 1 (20%) | 0 (0%) | 0 (0%) |
| No prior treatment | 1 (20%) | 4 (80%) | 8 (73%) |
| Total Fecal Samples | 19 | 22 | 27 |
| *1*Mean (SD); n (%); Sum; For SCC, the targeted agent was cetuximab; For BCC, the targeted agent was vismodegib | | | |